B1

C1 Cont



wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy[, hydroxy and halogen] when p is 2 and X is -O-;

[($R_1$) is $R_{20}$, $R_{21}$, or $R_{22}$, wherein:

$R_{20}$ is $-(CH_2)_n-$ where] n is 2, 3, 4 or 5;

[$R_{21}$ is

$-CH_2-CH=CH-CH_2-$,

$-CH_2-C\equiv C-CH_2-$,

$-CH_2-CH=CH-CH_2-CH_2-$,

$-CH_2-CH_2-CH=CH-CH_2-$,

$-CH_2C\equiv C-CH_2-CH_2-$, or

$-CH_2-CH_2-C\equiv C-CH_2-$,

the -CH=CH- bond being cis or trans;

$R_{22}$ is $R_{20}$ or $R_{21}$ in which one or more carbon atoms of $R_{20}$ or $R_{21}$ are substituted by at least one $C_1$-$C_6$ linear alkyl group, phenyl group or

lower alkyleneyl- 

;

where $Z_1$ is lower alkyl, -OH, lower alkoxy, $-CF_3$, $-NO_2$, $-NH_2$ or halogen;]

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, [monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,] -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, or -CH($OR_7$)-alkyl;[ -CH($OR^7$)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, and -C(=W)-heteroaryl;]

alkyl is lower alkyl;

aryl is phenyl or



;

where $R_5$ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine,

iodine, lower monoalkylamino, [lower dialkylamino,] nitro, cyano, trifluoromethyl, trifluoromethoxy;

B1

C1 Cont

heteroaryl is




;

$Q_3$ is -O-, -S-, -NH-, or -CH=N-;

[W is $CH_2$ or $CHR_8$ or N-$R_9$;]

$R_7$ is hydrogen, lower alkyl, or acyl;

[$R_8$ is lower alkyl;

$R_9$ is hydroxy, lower alkoxy, or -$NHR_{10}$; and

$R_{10}$ is hydrogen, lower alkyl, $C_1$-$C_3$ acyl, aryl, -C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above;] and

m is 1, 2, or 3;

[all geometric, optical and stereoisomers thereof,] or a pharmaceutically acceptable acid addition salt thereof.

---

B2

26. (Amended) A compound as claimed in claim 1, [which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl]-1-piperidinyl]-propoxy]-3-methylmercaptophenyl]ethanone or] <u>which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methylmercaptophenyl]ethanone or</u> a pharmaceutically acceptable acid addition salt thereof.

---

52. (Amended) A compound as claimed in claim [1] 132, which is N,N-dimethyl-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxybenzamide, or a pharmaceutically acceptable acid addition salt thereof.

B2

53. (Amended) A compound as claimed in claim [1] 132, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]ethanone oxime, or a pharmaceutically acceptable acid addition salt thereof.

54. (Amended) A compound as claimed in claim [1] 132, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]methoxyphenyl]ethanone oxime O-methyl ether, or a pharmaceutically acceptable acid addition salt thereof.

55. (Amended) A compound as claimed in claim [1] 132, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]ethanone hydrazone, or a pharmaceutically acceptable acid addition salt thereof.

56. (Amended) A compound as claimed in claim [1] 132, which is 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]-propyl]-4-piperidinyl]-1,2-benzisoxazole, or a pharmaceutically acceptable acid addition salt thereof.

57. (Amended) A compound as claimed in claim [1] 87, which is (Z)-1-[4-[[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

58. (Amended) A compound as claimed in claim [1] 87, which is (E)-1-[3-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-hydroxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

B3

59. (Twice Amended) A compound [as claimed in claim 1], which is (E)-1-[3-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-benzyloxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

---

---

65. (Twice Amended) A compound as claimed in claim [1, which is 1-(R)-(-)-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methyl-1-propoxy]-3-methoxyphenyl]ethanone, or] 104, which is 1-(R)-(-)-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methyl-1-propoxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

B4

66. (Amended) A compound as claimed in claim [1] 104, which is 1-(S)(+)-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methyl-1-propoxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

---

---

B5

74. (Amended) The compound of claim 1, wherein p is 2, X is -O-, and Y is [selected from the group consisting of] lower alkoxy[, hydroxy and halogen groups].

---

---

B6

77. (Amended) The compound of claim 1, wherein R is selected from the group consisting of hydrogen, $C_1$-$C_3$ alkyl, $C_1$-$C_3$ alkoxy, hydroxyl, -$COCF_3$, $C_1$-$C_6$ alkanoyl, Cl, F, Br,

I, $C_1$-$C_3$ alkylamino, [-$NO_3$] - $NO_2$, -$CF_3$, -$OCF_3$, and -C(=O)-lower alkyl.

B6

78. (Amended) A compound of the formula:



Sub D2

wherein p is 1 or 2;

Y is hydrogen, Cl, Br, or F, when p is 1;

Y is lower alkoxy[, hydroxy, or halogen] when p is 2;

n is 2, 3, or 4;

R is hydrogen, $C_1$-$C_3$ alkyl, $C_1$-$C_3$ alkoxy, hydroxyl, alkanoyl, Cl, F, Br, I, amino, $C_1$-$C_3$ mono or dialkyl amino, acylamino, -$NO_2$, -$OCF_3$, -$CF_3$, alkyl-C(=O)-, $CF_3$-C(=O)-, or -CH($OR_7$)-alkyl;

alkyl is lower alkyl;

$R_7$ is hydrogen, lower alkyl, lower alkyl-C(=O)-, or $CF_3$-C(=O)-;

and m is 1, 2, or 3;

all geometric, optical and stereoisomers thereof or a pharmaceutically acceptable acid addition salt thereof.

79. (Twice Amended) A compound of the formula:

B6



wherein p is 1 or 2;

Y is hydrogen, Cl, Br, or F, when p is 1;

Y is lower alkoxy[, hydroxy, or halogen] when p is 2;

n is 2, 3, or 4;

R is hydrogen, $C_1$-$C_3$ alkyl, $C_1$-$C_3$ alkoxy, hydroxyl, acyl, alkanoyl, Cl, F, Br, I, amino, $C_1$-$C_3$ mono or dialkyl amino, acylamino, $-NO_2$, $-OCF_3$, $-CF_3$, alkyl-C(=O)-, $CF_3$-C(=O)-, or $-CH(OR_7)$-alkyl;

alkyl is lower alkyl;

$R_7$ is hydrogen, lower alkyl, [or] lower alkyl-C(=O)-, or $CF_3$-C(=O)-;

and m is 1, 2, or 3;

all geometric, optical and stereoisomers thereof or a pharmaceutically acceptable acid addition salt thereof.

80. (Twice Amended) A compound as claimed in claim 1 [of the formula:



B6

C2 cont

wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy and halogen when p is 2 and X is -O-;

($R_1$) is $R_{20}$, $R_{21}$, or $R_{22}$, wherein:

$R_{20}$ is $-(CH_2)_{n-1}$ where n is 2, 3, 4 or 5;

$R_{21}$ is

$-CH_2-CH=CH-CH_2-$,

$-CH_2-C\equiv C-CH_2-$,

$-CH_2-CH=CH-CH_2-CH_2-$,

$-CH_2-CH_2-CH=CH-CH_2-$,

$-CH_2-C\equiv C-CH_2-CH_2-$, or

$-CH_2-CH_2-C\equiv C-CH_2-$,

the -CH=CH- bond being cis or trans;

$R_{22}$ is $R_{20}$ or $R_{21}$ in which one or more carbon atoms of $R_{20}$ or $R_{21}$ are substituted by at least one $C_1$-$C_6$ linear alkyl group, phenyl group or




;

where $Z_1$ is lower alkyl, -OH, lower alkoxy, $-CF_3$, $-NO_2$, $-NH_2$ or halogen; and R and m are as defined hereinafter;

m is 1, 2, or 3; and

B6
C.2
cont

when m is 1, 2, or 3, R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, -CH(OR$^7$)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, and -C(=W)-heteroaryl;

alkyl is lower alkyl;

aryl is phenyl or



;

where $R_5$ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy;

heteroaryl is



;

$Q_3$ is -O-, -S-, -NH-, or -CH=N-;

W is $CH_2$ or $CHR_8$ or N-$R_9$;

$R_7$ is hydrogen, lower alkyl, or acyl;

$R_8$ is lower alkyl;

$R_9$ is hydroxy, lower alkoxy, or -$NHR_{10}$; and

B6
C2
cont

$R_{10}$ is hydrogen, lower alkyl, $C_1$-$C_3$ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above; and]

with the proviso that when m is 3, R is not -C(=O)-heteroaryl[, or -C(=W)-heteroaryl;],

[all geometric, optical and stereoisomers thereof,] or a pharmaceutically acceptable acid addition salt thereof.

81. (Amended) A compound as claimed in claim [1] 87, which is (E)-1-[4-[[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

82. (Amended) A pharmaceutical composition, which comprises a compound as claimed in any one of claims [1-81] 1-75 and 77-81, and a pharmaceutically acceptable carrier therefor.

83. (Amended) An antipsychotic composition which comprises a compound as claimed in any one of claims [1-81] 1-75 and 77-81, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

84. (Amended) A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in any one of claims [1-81] 1-75 and 77-81.

85. (Amended) An analgesic composition which comprises a compound as claimed in any one of claims [1-81] 1-75 and 77-81, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

B6

86. (Amended) A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in any one of claims [1-81] 1-75 and 77-81.

Please amend claims 98, 114, 132, and 142, all added in the Preliminary Amendment dated November 15, 2000, as follows:

98. The compound of claim 87, wherein R is selected from the group consisting of hydrogen, $C_1$-$C_3$ alkyl, $C_1$-$C_3$ alkoxy, hydroxyl, -$COCF_3$, $C_1$-$C_6$ alkanoyl, Cl, F, Br, I, $C_1$-$C_3$ alkylamino, -$NO_2$, -$CF_3$, -$OCF_3$, and -C(=O)-lower alkyl.

B7

114. The compound of claim 104, wherein R is selected from the group consisting of hydrogen, $C_1$-$C_3$ alkyl, $C_1$-$C_3$ alkoxy, hydroxyl, -$COCF_3$, $C_1$-$C_6$ alkanoyl, Cl, F, Br, I, $C_1$-$C_3$ alkylamino, -$NO_2$, -$CF_3$, -$OCF_3$, and -C(=O)-lower alkyl.

B8

132. A compound of the formula



wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is -O-;

n is 2, 3, 4 or 5;

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, dialkylaminocarbonyl, formyl, -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, -CH($OR_7$)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, or -C(=W)-heteroaryl;

alkyl is lower alkyl;

aryl is phenyl or



;

B9

C5 Cont

where $R_5$ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy;

heteroaryl is




;

$Q_3$ is -O-, -S-, -NH-, or -CH=N-;

W is $CH_2$ or $CHR_8$ or N-$R_9$;

$R_7$ is hydrogen, lower alkyl, or acyl;

$R_8$ is lower alkyl;

$R_9$ is hydroxy, lower alkoxy, or -$NHR_{10}$; and

$R_{10}$ is hydrogen, lower alkyl, $C_1$-$C_3$ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above; and

m is 1, 2, or 3;

with the proviso that at least one R is selected from the group consisting of dialkylaminocarbonyl, formyl, -C(=W)-alkyl, -C(=W)-aryl, and -C(=W)-heteroaryl;

all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.